Cellulose Sodium Phosphate

CHEMBL1201457 Phase 4 승인됨 Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A non-absorbable ion exchange compound that binds calcium in the gastrointestinal tract and reduces urinary calcium excretion, historically used to prevent kidney stones in patients with absorptive hypercalciuria. It does not enter the bloodstream and acts entirely within the gut. It requires careful dietary management and supplementation to prevent secondary hyperparathyroidism.

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A non-absorbable ion exchange compound that binds calcium in the gastrointestinal tract and reduces urinary calcium excretion, historically used to prevent kidney stones in patients with absorptive hypercalciuria. It does not enter the bloodstream and acts entirely within the gut. It requires careful dietary management and supplementation to prevent secondary hyperparathyroidism.

Yes, Cellulose Sodium Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201457. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.